Biopsy rates, which had soared early in the 1990s with the introduction of the PSA assay, have fallen dramatically and the incidence of prostate cancer has stabilized, according to a study from the University of Southern California, Los Angeles.
Biopsy rates, which had soared early in the 1990s with the introduction of the PSA assay, have fallen dramatically and the incidence of prostate cancer has stabilized, according to a study from the University of Southern California, Los Angeles.
"Doctors are selecting more appropriate patients for biopsy, as evidenced by the observation that the biopsy rates are falling while the incidence of prostate cancer detection has remained stable since 1995. We are getting better at what we do, and we are using the technology more appropriately," David F. Penson, MD, MPH, associate professor at the USC Norris Cancer Center, told Urology Times.
Dr. Penson and his colleagues sifted through 1.3 million Medicare records to determine biopsy rates and TRUS utilization during 1992, 1995, 1998, and 2001.Changes recorded by Dr. Penson during the 9-year period were substantial. The number of biopsies conducted on men fell from 2,893 per 100,000 in 1992 to 1,602 in 2001, a decline of 44.6%. Biopsy rates by racial group reversed during the years measured. In 1992, the Caucasian biopsy rate exceeded that for African-Americans: 2,963 per 100,000 for Caucasians and 2,676 per 100,000 for African-Americans. Nine years later, the African-American rate exceeded the Caucasian rate: 1,594 per 100,000 for Caucasians compared with 1,733 per 100,000 for African-Americans.
The percentage of biopsies taken under the guidance of transrectal ultrasonography nearly doubled. In 1991, 36.9% of all biopsies used TRUS. This percentage rose to 67.9% by 2001.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.